<< Factors affecting survival, disability of extremely premature infants identified | New less traumatic way of delivering surfactant to help preemies breathe could reduce chronic lung disease >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Dansk | Nederlands | Русский | Svenska | Polski

Medicare costs estimated at $21.1 billion for 5 years of care for elderly cancer patients

Published on April 29, 2008 at 6:21 PM · No Comments

The cost of cancer care for elderly Medicare patients varies by tumor type, stage at diagnosis, phase of care, and survival, according to a new study published online April 29 in the Journal of the National Cancer Institute.

The 5-year cost is highest for patients with lung, colorectal, and prostate cancers. The estimated cost for 5 years of care for elderly Medicare patients diagnosed with cancer in 2004 is $21.1 billion.

Cost estimates for cancer care are useful for the development and implementation of national cancer programs and policies. As the United States population expands and ages, the incidence of cancer and its associated costs are expected to rise.

To estimate the cost of cancer care in the U.S., Robin Yabroff, Ph.D., of the National Cancer Institute in Bethesda, Md., and colleagues used the Surveillance, Epidemiology, and End Results (SEER) and SEER-linked Medicare files to identify 718,907 cancer patients and 1,623,651 control subjects without cancer. The team subtracted the Medicare expenses for matched control subjects from the Medicare expenses for individuals diagnosed with cancer. The balance was the estimated net cost of cancer care per individual.

The mean net 5-year costs of care for elderly individuals varied widely, from less than $20,000 for patients with breast cancer or melanoma to more than $40,000 for patients with lymphoma, brain or other nervous system cancers, or cancers of the esophagus, ovaries, or stomach. Across all cancers, mean net costs were highest in the first 12 months of care and the last 12 months of life, and lowest in the period between the initial phase of care and last year of life.

Yabroff and colleagues note that the study does not evaluate the cost of care in younger cancer patients. As these individuals frequently opt for more aggressive therapies, the cost of services may differ from those reported here. Additionally, as newer, more expensive therapies become routine care, the costs could climb.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading